Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

Related Articles by Review for PubMed (Select 18723490)

1.

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.

Kitagaki J, Agama KK, Pommier Y, Yang Y, Weissman AM.

Mol Cancer Ther. 2008 Aug;7(8):2445-54. doi: 10.1158/1535-7163.MCT-08-0063.

2.

[Abnormal p53-HDM2 interaction in hematological malignancy].

Tabe Y, Kojima K.

Nihon Rinsho. 2014 Jun;72(6):1042-6. Review. Japanese.

PMID:
25016801
3.

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.

Patel S, Player MR.

Expert Opin Investig Drugs. 2008 Dec;17(12):1865-82. doi: 10.1517/13543780802493366 . Review.

PMID:
19012502
4.

Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.

Di J, Zhang Y, Zheng J.

Curr Cancer Drug Targets. 2011 Oct;11(8):987-94. Review.

PMID:
21762075
5.
6.

Unlocking the Mdm2-p53 loop: ubiquitin is the key.

Clegg HV, Itahana K, Zhang Y.

Cell Cycle. 2008 Feb 1;7(3):287-92. Epub 2007 Nov 25. Review.

7.

ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.

Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG.

Cell Cycle. 2005 Sep;4(9):1166-70. Epub 2005 Sep 29. Review.

8.

Network perspectives on HDM2 inhibitor chemotherapy combinations.

Azmi AS, Beck FW, Sarkar FH, Mohammad RM.

Curr Pharm Des. 2011;17(6):640-52. Review.

PMID:
21391913
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk